Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes

The Journal of Experimental Medicine, Journal Year: 2025, Volume and Issue: 222(4)

Published: Jan. 17, 2025

Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the route and dose from 5 × 105 CFUs ID to 107 i.v. resulted prevention of Mycobacterium tuberculosis (Mtb) infection TB disease highly susceptible nonhuman primates. Identifying immune mechanisms protection following will facilitate development more effective vaccines against TB. Here, we depleted lymphocyte subsets prior during Mtb challenge BCG-vaccinated macaques identify those necessary for protection. Depletion adaptive CD4 T cells, but not CD8αβ loss with increased burdens dissemination, indicating cells are critical BCG-mediated unconventional CD8α-expressing lymphocytes (NK innate CD4+CD8α+ double-positive cells) abrogated most BCG-immunized macaques, supporting further investigation into which these cell contribute after vaccination.

Language: Английский

CD4 T cells and CD8α+ lymphocytes are necessary for intravenous BCG-induced protection against tuberculosis in macaques

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 17, 2024

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the route dose from 5×10

Language: Английский